Evidence map›Paper›PMID 18160464›Full record

ArticleThe Journal of clinical endocrinology and metabolism2008

Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage.

Megan Rist Haymart, Daniel John Repplinger, Glen E Leverson, Diane F Elson, Rebecca S Sippel, Juan Carlos Jaume, Herbert Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 207 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
207citing papers in PubMed, 15 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

207 citing papers in PubMed, 15 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. The Breast-Thyroid Cancer Link: A Systematic Review and Meta-analysis.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2016
    Pooled it
  12. Guideline
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Trial
  17. Article
  18. Article
  19. Article
  20. Article

147 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Megan Rist HaymartDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Wisconsin, Madison, Wisconsin 53792, USA.
Daniel John Repplinger
Glen E Leverson
Diane F Elson
Rebecca S Sippel
Juan Carlos Jaume
Herbert Chen

Funding

Surgery Summer Research Experience for Medical StudentsT35DK062709 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI MEZRICH, JOSHUA D · 2006 to 2023
$870k
NIDDK NIH HHS T35 DK062709
6 · The paper itself

Abstract

contextTSH is a known thyroid growth factor, but the pathogenic role of TSH in thyroid oncogenesis is unclear.

objectiveThe aim was to examine the relationship between preoperative TSH and differentiated thyroid cancer (DTC).

designThe design was a retrospective cohort. SETTING,

participantsBetween May 1994 and January 2007, 1198 patients underwent thyroid surgery at a single hospital. Data from the 843 patients with preoperative serum TSH concentration were recorded.

main outcome measuresSerum TSH concentration was measured with a sensitive assay. Diagnoses of DTC vs. benign thyroid disease were based on surgical pathology reports.

resultsTwenty-nine percent of patients (241 of 843) had DTC on final pathology. On both univariate and multivariable analyses, risk of malignancy correlated with higher TSH level (P=0.007). The likelihood of malignancy was 16% (nine of 55) when TSH was less than 0.06 mIU/liter vs. 52% (15 of 29) when 5.00 mIU/liter or greater (P=0.001). When TSH was between 0.40 and 1.39 mIU/liter, the likelihood of malignancy was 25% (85 of 347) vs. 35% (109 of 308) when TSH was between 1.40 and 4.99 mIU/liter (P=0.002). The mean TSH was 4.9+/-1.5 mIU/liter in patients with stage III/IV disease vs. 2.1+/-0.2 mIU/liter in patients with stage I/II disease (P=0.002).

conclusionsThe likelihood of thyroid cancer increases with higher serum TSH concentration. Even within normal TSH ranges, a TSH level above the population mean is associated with significantly greater likelihood of thyroid cancer than a TSH below the mean. Shown for the first time, higher TSH level is associated with advanced stage DTC.

Indexed as

AdultBiopsy, NeedleFemaleHumansMaleMiddle AgedMutationNeoplasm StagingReceptors, ThyrotropinRetrospective StudiesRiskThyroid NeoplasmsThyroid NoduleThyrotropinReceptors, ThyrotropinThyrotropin

Identifiers

PMID18160464
PMCPMC2266959

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.